These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6718347)

  • 21. [Effectiveness of alpha-tocopherol in eliminating and preventing the hepatotoxic action of tuberculostatics].
    Grechin SA; Suslov EI; Mel'nik VP; Shuripa VP; Protsiuk RG
    Vrach Delo; 1987 Mar; (3):60-2. PubMed ID: 3590706
    [No Abstract]   [Full Text] [Related]  

  • 22. [Levamisole treatment of experimental tuberculosis].
    Aleksandrova AE; Zabolotnykh NV
    Probl Tuberk; 1981 Oct; (10):55-8. PubMed ID: 7312854
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of antitubercular preparations on the myocardium of healthy and tuberculosis-infected rabbits].
    Iakovleva TA; Eskunov PN
    Probl Tuberk; 1982 Jun; (6):70-4. PubMed ID: 7122468
    [No Abstract]   [Full Text] [Related]  

  • 24. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 25. Medicine. A portfolio model of drug development for tuberculosis.
    Glickman SW; Rasiel EB; Hamilton CD; Kubataev A; Schulman KA
    Science; 2006 Mar; 311(5765):1246-7. PubMed ID: 16513969
    [No Abstract]   [Full Text] [Related]  

  • 26. [Macrophage migration inhibition reaction as an index of the effectiveness of the intermittent and continuous chemotherapy of tuberculosis].
    Sibirnaia RI
    Probl Tuberk; 1980 Sep; (9):69-71. PubMed ID: 7422664
    [No Abstract]   [Full Text] [Related]  

  • 27. [Role of the blood kinin system in the course of the reparation processes in tuberculosis].
    Makinskiĭ AI; Solov'eva IP
    Vrach Delo; 1986 Dec; (12):78-80. PubMed ID: 3548065
    [No Abstract]   [Full Text] [Related]  

  • 28. Further acquisition of drug-resistance in multidrug-resistant tuberculosis during chemotherapy.
    Toyota E; Sekiguchi J; Shimizu H; Fujino T; Otsuka Y; Yoshikura H; Kuratsuji T; Kirikae T; Kudo K
    Jpn J Infect Dis; 2004 Dec; 57(6):292-4. PubMed ID: 15623961
    [No Abstract]   [Full Text] [Related]  

  • 29. [Maxaquin in the combined treatment of tuberculosis].
    Sokolova GB; Mozhokina GN; Kunichan AD; Elistratova NA; Perel'man MI
    Probl Tuberk; 2000; (5):35-9. PubMed ID: 11077850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preclinical evaluation of alboverticillin, triculamine, and o-carbamyl-d-serine as a new antituberculous antibiotic].
    Kanai K; Koseki Y; Nakamura R; Okamoto S; Murohashi T
    Kekkaku; 1967 Jan; 42(1):37-42. PubMed ID: 6036570
    [No Abstract]   [Full Text] [Related]  

  • 31. [Short-term chemotherapy in tuberculosis].
    Ionescu C; Mihăescu T
    Rev Med Chir Soc Med Nat Iasi; 1988; Suppl():35-41. PubMed ID: 3075796
    [No Abstract]   [Full Text] [Related]  

  • 32. [Dynamics of the experimental tuberculous process under the influence of nerobol].
    Gomoliako IV; Bal'tseva LB; Klimenko MT
    Probl Tuberk; 1980 Jan; (1):60-3. PubMed ID: 7367427
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of 4,4'-diisoamyloxythiocarbanilide (Isoxyl) in the experimental guinea pig tuberculosis].
    Nakamura R; Koseki Y; Murohashi T
    Kekkaku; 1965 Aug; 40(8):303-6. PubMed ID: 5860857
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of tuberculosis].
    Soto-Ramírez LE
    Gac Med Mex; 1997; 133(6):613-6. PubMed ID: 9504090
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of sodium nucleinate on the development of morphologic reactions during antibacterial therapy of experimental tuberculosis].
    Baranova TV
    Probl Tuberk; 1986; (12):46-50. PubMed ID: 3823082
    [No Abstract]   [Full Text] [Related]  

  • 36. Nanotechnology based drug delivery system(s) for the management of tuberculosis.
    Pandey R; Khuller GK
    Indian J Exp Biol; 2006 May; 44(5):357-66. PubMed ID: 16708887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rising standards for tuberculosis drug development.
    Balganesh TS; Alzari PM; Cole ST
    Trends Pharmacol Sci; 2008 Nov; 29(11):576-81. PubMed ID: 18799223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tuberculosis in immigrants recently arrived in Barcelona].
    Saravanja M; Terre M; Ros M; Bada JL
    Med Clin (Barc); 1999 Mar; 112(9):359. PubMed ID: 10220773
    [No Abstract]   [Full Text] [Related]  

  • 40. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.